About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
GWPH - GW Pharmaceuticals P...| Previous Close | $102.01 | Open | $101.90 |
| Volume | 659K | Market Cap | 3.177B |
| Yield | Last Dividend |
| Better Cannabis Stock: Charlotte's Web v... | 09/03/20 |
| In a complicated legal landscape, one FDA-approved cannabis product can help investors pick the winner. | |
| Top Analyst Upgrades and Downgrades: Cro... | 08/25/20 |
| No summary available. | |
| GW Pharmaceuticals PLC (GWPH) Q2 2020 Ea... | 08/11/20 |
| GW Pharmaceuticals PLC (NASDAQ: GWPH) Q2 2020 earnings conference call dated August 06, 2020 | |
| The Week In Cannabis: FDA Approves Epidi... | 08/07/20 |
| In a week where markets were up, cannabis stocks were mostly declining. The week started off on a good note, with GW Pharmaceuticals PLC- ADR (NASDAQ:... | |
| GW Pharma shares slide 12% after company... | 08/07/20 |
| Shares of GW Pharmaceuticals PLC undefined slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coro... | |
| GW Pharmaceuticals plc Reports Second Qu... | 08/06/20 |
| - Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month... | |
| GW Pharmaceuticals Q2 2020 Earnings Prev... | 08/05/20 |
| GW Pharmaceuticals (NASDAQ:GWPH) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate ... | |
| FDA Approves CBD Meds From GW Pharmaceut... | 08/03/20 |
| GW Pharmaceuticals plc (NASDAQ: GWPH ) and Greenwich Biosciences Inc. jointly announced FDA approval for EPIDIOLEX , an oral solution aimed to manage ... | |
| GW Pharmaceuticals Announces FDA Approva... | 08/03/20 |
| This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of ??... | |
| GW Pharma Scores New FDA Approval For CB... | 08/03/20 |
| Cannabis stock GW Pharma (GWPH) has announced that the U.S. The post GW Pharma Scores New FDA Approval For CBD Drug Epidiolex appeared first on Smarte... | |
| The Daily Biotech Pulse: Sanofi-GSK Land... | 07/31/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 30) Achieve Life Sciences Inc (NASDAQ: ACHV) Annexon Inc (NASDAQ: ANNX) (IPOed July ??? | |
| The Week Ahead In Biotech: Spotlight On ... | 07/26/20 |
| Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there... | |
| Top Analyst Upgrades and Downgrades: App... | 07/15/20 |
| No summary available. | |
| GW Pharmaceuticals stock slips after Sti... | 07/15/20 |
| Shares of GW Pharmaceuticals PLC undefined fell 0.4% in premarket trading, after Stifel Nicolaus analyst Paul Matteis downgraded the maker of the??? | |
| Cannabis Stock Gainers And Losers From J... | 07/14/20 |
| Gainers BIOHARVEST SCIENCES INC (OTC: CNVCF) shares closed up 29.55% at $0.10 Intec Pharma (NASDAQ: NTEC ) shares closed up 13.83% at $0.30 Bloom Ener... | |
| GW Pharma Makes Big Regulatory Step for ... | 06/24/20 |
| No summary available. | |
| UK Relaxes Rules On GWPH Cannabis Drug E... | 06/24/20 |
| Cannabis stock GW Pharma (GWPH) has announced that the UK Home Office has lowered its classification of Epidyolex (cannabidiol). This change will take... | |
| 'Dr Pot' stashes away a cannabis fortune... | 06/20/20 |
| Dr Geoffrey Guy (pictured), who earned the nickname after founding Cambridge-based GW Pharmaceuticals in 1998, made ??5.8million in 2019 as the compan... | |
| GW Pharmaceuticals (GWPH): Investments i... | 05/12/20 |
| GW Pharmaceuticals plc (NASDAQ: GWPH) has seen its stock gain over 17% in the past one month. The company delivered topline growth of over 200% in the... | |
| GW Pharma Pops 9% After-Hours As Epidiol... | 05/12/20 |
| Cannabinoid prescription medicines stock GW Pharmaceuticals (GWPH) has reported particularly strong first quarter earnings results, with US sales of E... | |
| GW Pharmaceuticals sells more of CBD-der... | 05/11/20 |
| GW Pharmaceuticals PLC undefined shares rose 2.6% in the extended session Monday after the U.K.-based company sold much more of its cannabis derived e... | |
| GW Pharmaceuticals plc Reports First Qua... | 05/11/20 |
| - Total revenue of $120.6 million - - Total Epidiolex?? net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT ??? LONDON and?... | |
| insurance market UAE, United Arab Emirat... | 04/29/20 |
| UAE Online Insurance Industry, Motor Insurance Declining Premium UAE, Life Insurance GWP Online UAE, Individual Life GWP Online UAE, Online Brokers in... | |
| The Week In Cannabis: Charlotte Figi's P... | 04/12/20 |
| A shortened week came with a no shortage of news for the cannabis community and industry. We must start with a deeply sad event: the passing of 13-yea... | |
| DEA Deschedules Expidiolex; GW Pharma's ... | 04/07/20 |
| GW Pharmaceuticals plc (NASDAQ: GWPH ) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiole... | |
| GW Pharma News: GWPH Stock Jumps 6% on E... | 04/06/20 |
| GW Pharma (GWPH) news for Monday concerning the descheduling of Epidiolex as a Schedule V drug by the DEA has GWPH stock rising. | |
| The Week In Cannabis: Stocks Back In The... | 04/05/20 |
| After two strong weeks, marijuana stocks went negative again, with all major ETFs posting significant losses. Over the last five trading days: The ETF... | |
| Buy rating | 08/07/20 |
| Needham maintains Buy rating and lowers Price Target from $190.00 to $180.00 | |
| Buy rating | 08/07/20 |
| HC Wainwright & Co. maintains Buy rating and lowers Price Target from $164.00 to $162.00 | |
| Buy rating | 08/04/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $161.00 to $164.00 | |
| Hold rating | 07/15/20 |
| Stifel downgrades from Buy to Hold rating and lowers Price Target from $150.00 to $140.00 | |
| Date | 2020-08-06 (AMC) | Est. (EPS/Rev.) | ($0.63)/ 120.31M |
| Actual (EPS/Rev.) | $-0.02/ $121.30 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| High Growth Stocks- Long only | Srini Donapati | 69.00 % | Follow |
| Biotech picks | mr jackson | 50.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
